Investigational drug · Phase 2
GB221
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Spinal Muscular Atrophy Type I.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
6
Any phase or sponsor naming "GB221"
First trial start
2026
Jan 6, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GB221", any sponsor or status.
Conditions studied
As listed on its trial records.
- Spinal Muscular Atrophy Type I
Approved drugs for the same conditions: Spinal muscular atrophy · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "GB221" as an intervention, largest first.
- Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody (GB221) for InjectionPivotal-lookingStatus unknown
Genor Biopharma Co., Ltd.Industry
NCT04164615 · 336 participants (planned) · Start Nov 24, 2016 · Primary completion Jul 2020
Drug: GB221; Placebo control · For: HER-2-positive Advanced Breast Cancer
Sites: Beijing, China
- Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for InjectionPivotal-lookingStatus unknown
Genor Biopharma Co., Ltd.Industry
NCT04170595 · 132 participants (planned) · Start Mar 28, 2014 · Primary completion Dec 2021
Drug: GB221,2 mg/kg; GB221,6 mg/kg and 4 more · For: HER2-positive Breast Cancer
Sites: Beijing, China
Genor Biopharma Co., Ltd.Industry
NCT04905667 · 87 participants · Start Nov 13, 2019 · Primary completion Sep 8, 2020
Drug: GB221; Herceptin · For: Breast Cancer
Sites: Guangzhou, China
Genor Biopharma Co., Ltd.Industry
NCT04175171 · 32 participants · Start Nov 7, 2011 · Primary completion Jan 8, 2012
Drug: Coprelotamab Injection; Trastuzumab Injection · For: Metastatic Breast Cancer
Sites: Nedlands, Australia
Veana TherapeuticsIndustry
NCT04120246 · 24 participants (planned) · Start Apr 8, 2020 · Primary completion Feb 1, 2028
Drug: Alpha-tocopheryloxyacetic Acid; Trastuzumab · For: Anatomic Stage IV Breast Cancer AJCC v8; HER2 Positive Breast Carcinoma; Metastatic Breast Carcinoma and 1 more
Sites: Portland, Oregon; Seattle, Washington
- Study of Safety, Tolerability and Efficacy of GB221 in Infants With Spinal Muscular Atrophy Type 1Recruiting
Gemma BiotherapeuticsIndustry
NCT07070999 · 22 participants (planned) · Start Jan 6, 2026 · Primary completion Dec 2028
Drug: GB221 · For: Spinal Muscular Atrophy Type I
Sites: Porto Alegre, Brazil
Newest research
PubMed records naming it or its code names, newest first.
- A Phase I Clinical Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of GB221 Injection and Trastuzumab (Herceptin®) in Healthy Chinese Adults.
Zhu Y, Li C, Chen L, et al. · Eur J Drug Metab Pharmacokinet 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.